Yasuyoshi Morita

676 total citations
53 papers, 333 citations indexed

About

Yasuyoshi Morita is a scholar working on Hematology, Immunology and Genetics. According to data from OpenAlex, Yasuyoshi Morita has authored 53 papers receiving a total of 333 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Hematology, 17 papers in Immunology and 16 papers in Genetics. Recurrent topics in Yasuyoshi Morita's work include Acute Myeloid Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (13 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Yasuyoshi Morita is often cited by papers focused on Acute Myeloid Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (13 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Yasuyoshi Morita collaborates with scholars based in Japan, United States and Taiwan. Yasuyoshi Morita's co-authors include Itaru Matsumura, Hirokazu Tanaka, Shinya Rai, Yasuhiro Maeda, Yoichi Tatsumi, J. Luis Espinoza, Takashi Ashida, Akihisa Kanamaru, Yuzuru Kanakura and Mitsuhiro Matsuda and has published in prestigious journals such as Blood, PLoS ONE and Biochemical and Biophysical Research Communications.

In The Last Decade

Yasuyoshi Morita

47 papers receiving 328 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yasuyoshi Morita Japan 11 132 123 101 80 60 53 333
Hajime Yasuda Japan 11 93 0.7× 115 0.9× 66 0.7× 74 0.9× 73 1.2× 55 366
László Gopcsa Hungary 13 132 1.0× 53 0.4× 100 1.0× 79 1.0× 55 0.9× 44 339
Solomon I. Hamburg United States 11 92 0.7× 73 0.6× 91 0.9× 130 1.6× 26 0.4× 22 325
Andreza Alice Feitosa Ribeiro Brazil 12 251 1.9× 133 1.1× 112 1.1× 32 0.4× 32 0.5× 44 456
Loretta Pfannes United States 9 229 1.7× 81 0.7× 109 1.1× 125 1.6× 12 0.2× 19 373
Gradimir Janković Serbia 13 246 1.9× 209 1.7× 47 0.5× 102 1.3× 85 1.4× 50 437
Seiichiro Katagiri Japan 14 207 1.6× 116 0.9× 65 0.6× 199 2.5× 36 0.6× 59 498
Fuad V. Shammas Norway 11 122 0.9× 45 0.4× 57 0.6× 68 0.8× 24 0.4× 13 349
Zonghong Shao China 12 197 1.5× 52 0.4× 228 2.3× 58 0.7× 16 0.3× 68 384
Adrian Duek Israel 10 241 1.8× 201 1.6× 55 0.5× 182 2.3× 30 0.5× 34 397

Countries citing papers authored by Yasuyoshi Morita

Since Specialization
Citations

This map shows the geographic impact of Yasuyoshi Morita's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasuyoshi Morita with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasuyoshi Morita more than expected).

Fields of papers citing papers by Yasuyoshi Morita

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yasuyoshi Morita. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasuyoshi Morita. The network helps show where Yasuyoshi Morita may publish in the future.

Co-authorship network of co-authors of Yasuyoshi Morita

This figure shows the co-authorship network connecting the top 25 collaborators of Yasuyoshi Morita. A scholar is included among the top collaborators of Yasuyoshi Morita based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yasuyoshi Morita. Yasuyoshi Morita is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tanaka, Hirokazu, Ryosuke Fujiwara, Yasuyoshi Morita, et al.. (2025). Antipsychotic Chlorpromazine Suppresses STAT5 Signaling, Overcomes Resistance Mediated by the Gatekeeper Mutation FLT3-ITD/F691L, and Synergizes with Quizartinib in FLT3-ITD-Positive Cells. Current Issues in Molecular Biology. 47(10). 797–797.
2.
Lee, Jong Wook, Jun Ho Jang, Hirohito Yamazaki, et al.. (2025). Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia. Blood Advances. 9(22). 5732–5735. 1 indexed citations
3.
Chang, Chunkang, Takahiro Suzuki, Yang Liang, et al.. (2025). Safety and efficacy of luspatercept in treating anemia associated with myelodysplastic syndrome with ring sideroblasts in Asian patients who require red blood cell transfusions: a phase II bridging study. Therapeutic Advances in Hematology. 16. 1584239475–1584239475. 1 indexed citations
4.
Taniguchi, Takahide, Shoko Nakayama, Hirokazu Tanaka, et al.. (2022). Novel prognostic predictor of haemoglobin–platelet index in diffuse large B‐cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL‐6 production in lymphoma cells. British Journal of Haematology. 198(2). 360–372. 2 indexed citations
5.
Tanaka, Hirokazu, Shinya Rai, Yasuhiro Taniguchi, et al.. (2022). C-type lectin-like receptor 2 specifies a functionally distinct subpopulation within phenotypically defined hematopoietic stem cell population that contribute to emergent megakaryopoiesis. International Journal of Hematology. 115(3). 310–321. 1 indexed citations
6.
Tanaka, Hirokazu, Takeshi Ueda, Takahide Taniguchi, et al.. (2022). CD34+ myeloma cells with self-renewal activities are therapy-resistant and persist as MRD in cell cycle quiescence. International Journal of Hematology. 115(3). 336–349. 3 indexed citations
7.
Fujiwara, Ryosuke, Yasuhiro Taniguchi, Shinya Rai, et al.. (2022). Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells. Biochemical and Biophysical Research Communications. 626. 156–166. 10 indexed citations
8.
Rai, Shinya, Hiroaki Inoue, Kazuko Sakai, et al.. (2021). Decreased expression of T‐cell‐associated immune markers predicts poor prognosis in patients with follicular lymphoma. Cancer Science. 113(2). 660–673. 11 indexed citations
9.
10.
Inoue, Hiroaki, Shinya Rai, Hirokazu Tanaka, et al.. (2020). Epstein–Barr Virus-Induced Post-Transplant Lymphoproliferative Disorder of the Central Nervous System Successfully Treated with Chemo-Immunotherapy. Viruses. 12(4). 416–416. 2 indexed citations
11.
Inoue, Hiroaki, Shinya Rai, Hirokazu Tanaka, et al.. (2020). Tumour‐immune microenvironment in duodenal‐type follicular lymphoma. British Journal of Haematology. 191(2). 243–252. 8 indexed citations
12.
Tanaka, Hirokazu, J. Luis Espinoza, Ryosuke Fujiwara, et al.. (2019). Excessive Reactive Iron Impairs Hematopoiesis by Affecting Both Immature Hematopoietic Cells and Stromal Cells. Cells. 8(3). 226–226. 29 indexed citations
13.
Taniguchi, Takahide, Shoko Nakayama, Yasuyoshi Morita, et al.. (2018). Antidiuretic hormone‐ and interleukin‐6‐producing angioimmunoblastic T‐cell lymphoma associated with syndrome of inappropriate antidiuretic hormone secretion. British Journal of Haematology. 184(2). 121–121.
14.
Rai, Shinya, Hirokazu Tanaka, Hiroaki Inoue, et al.. (2018). Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab. Cancers. 10(9). 304–304. 1 indexed citations
15.
Morita, Yasuyoshi, Yasuhiro Maeda, Terufumi Yamaguchi, et al.. (2018). Five‐day regimen of azacitidine for lower‐risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single‐arm phase 2 trial. Cancer Science. 109(10). 3209–3215. 10 indexed citations
16.
17.
Inoue, Hiroaki, Yasuyoshi Morita, Shinya Rai, et al.. (2017). Azacitidine therapy for low-risk myelodysplastic syndrome developing after solid organ transplantation.. PubMed. 58(2). 138–142.
18.
Miyasaka, Naoyuki, Osamu Miura, Tatsuya Kawaguchi, et al.. (2016). Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. International Journal of Hematology. 103(6). 703–712. 38 indexed citations
19.
Morita, Yasuyoshi, Akihisa Kanamaru, Yasushi Miyazaki, et al.. (2010). Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. International Journal of Hematology. 91(1). 97–103. 13 indexed citations
20.
Morita, Yasuyoshi, Mitsuhiro Matsuda, Hitoshi Hanamoto, et al.. (2004). A perforin/granzyme-positive MDS-derived T cell line, K2-MDS, induces apoptosis in CD34+ cells through the fractalkine–CX3CR1 system. Clinical Immunology. 113(1). 109–116. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hajime Yasuda Breakdown of academic impact, for papers by László Gopcsa Breakdown of academic impact, for papers by Solomon I. Hamburg Breakdown of academic impact, for papers by Andreza Alice Feitosa Ribeiro Breakdown of academic impact, for papers by Loretta Pfannes Breakdown of academic impact, for papers by Gradimir Janković Breakdown of academic impact, for papers by Seiichiro Katagiri Breakdown of academic impact, for papers by Fuad V. Shammas Breakdown of academic impact, for papers by Zonghong Shao Breakdown of academic impact, for papers by Adrian Duek
Rankless by CCL
2026